NYSE · Healthcare
BAXTER INTERNATIONAL INC (BAX)
As-reported financials and recent SEC filings for BAXTER INTERNATIONAL INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$11.24B
Net income
$-957.0M
Net margin
-8.5%
Diluted EPS
$-1.87
ROE
-15.7%
P/E (TTM)
—
Market cap
$11.38B
Debt / equity
1.6×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $11.24B | $10.64B | $10.36B | $10.06B | $12.15B |
| Gross profit | $3.38B | $3.98B | $4.15B | $3.55B | $4.72B |
| Operating income | $-308.0M | $14.0M | $707.0M | $-2.85B | $1.35B |
| Net income | $-957.0M | $-649.0M | $2.66B | $-2.43B | $1.28B |
| Diluted EPS | $-1.87 | $-1.27 | $5.23 | $-4.83 | $2.53 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
SCHEDULE 13G/A2026-06-05
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →SD2026-05-29
View on EDGAR →1442026-05-18
View on EDGAR →S-82026-05-08
View on EDGAR →8-K2026-05-08
View on EDGAR →Go deeper on BAX
Search BAXTER INTERNATIONAL INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.